American Statistical Association
Asserting pathogenicity to germline variants is at the core of genetic risk estimation. However, pathogenicity assessment is a multistep, multimodal exercise. The talk will focus on the automation of the ACMG criteria for pathogenicity estimation in our algorithm PathoMAN. In this context, I will also discuss the germline mutation landscape in 20,000 cancer patients sequenced using the MSK-IMPACT assay.
|Date:||Wednesday, March 13, 2019|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan Kettering Cancer Center
Department of Epidemiology and Biostatistics
485 Lexington Avenue
(Between 46th & 47th Streets)
2nd Floor, Conference Room B
New York, New York
**Outside visitors please email firstname.lastname@example.org for building access. You must be on the security list to enter the floor.